Hengrui Pharma's stock surged 10.65% in the pre-market trading session on Monday, following the announcement of a significant licensing agreement with global pharmaceutical giant GSK. The deal grants GSK exclusive rights to Hengrui's HRS-9821 project and options for up to 11 additional projects, excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan.
According to the terms of the agreement, GSK will make an initial payment of $500 million to Hengrui Pharma. The Chinese pharmaceutical company stands to potentially receive a total of approximately $12 billion if all projects are granted exclusive options and all development, registration, and sales milestones are achieved successfully.
This substantial deal represents a major breakthrough for Hengrui Pharma, significantly boosting its global presence and financial prospects. The market's enthusiastic response, as evidenced by the sharp rise in stock price, reflects investors' optimism about the company's future growth potential and the validation of its drug development capabilities by a leading international pharmaceutical company.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。